Literature DB >> 19566117

Therapeutic drug monitoring of aminoglycosides in neonates.

Matthijs de Hoog, John N van den Anker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19566117     DOI： 10.2165/00003088-200948050-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  8 in total

Review 1.  One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.

Authors:  S C Rao; M Ahmed; R Hagan
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.

Authors:  Matthijs de Hoog; Johan W Mouton; Rik C Schoemaker; Cees M Verduin; John N van den Anker
Journal:  Clin Pharmacol Ther       Date:  2002-05       Impact factor: 6.875

3.  Risk factors of sensorineural hearing loss in preterm infants.

Authors:  C Borradori; C L Fawer; T Buclin; A Calame
Journal:  Biol Neonate       Date:  1997

Review 4.  Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.

Authors:  E Nestaas; H-J Bangstad; L Sandvik; K-O Wathne
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-04-27       Impact factor: 5.747

Review 5.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

7.  Renal function in premature infants during aminoglycoside therapy.

Authors:  V I Giapros; S Andronikou; V I Cholevas; Z L Papadopoulou
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

8.  Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.

Authors:  Matthijs de Hoog; Bert A van Zanten; Wim C Hop; Ellen Overbosch; Nynke Weisglas-Kuperus; John N van den Anker
Journal:  J Pediatr       Date:  2003-01       Impact factor: 4.406
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.